ESMO 2021: Alternative treatment schedule for ipilimumab plus nivolumab in first-line treatment of advanced RCC (PRISM)
Ipilimumab plus nivolumab is a standard first-line treatment for patients [...]
Ipilimumab plus nivolumab is a standard first-line treatment for patients [...]